Reviewer's report

Title: Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS)

Version: 4
Date: 5 March 2015

Reviewer: Imre Pavo

Reviewer's report:

All major compulsory objections, essential revisions has been performed and addressed as much as the general limitations around the study allowed. The manuscript improved by these revisions.

Major Compulsory Revisions

NO

Minor Essential Revisions

Discretionary Revisions

line 30: would suggest "not statistically different" instead of "numerically similar"
line 249: would suggest a more descriptive subtitle like: "Impact of changes in health reimbursement system on prescription habits..." or similar
line 271: similarly. "Impact of EU license changes on prescription habits..."?
line 347: do you want to say "homogenous"? not "similar"?
line 348: "insights" rather than "suggestions"

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

As stated already at the first review, I am full time employee and shareholder of Eli Lilly and Co, the manufacturer of teriparatide. I did not have, however, any relationship with the current study.